Skip to content
Clinical ResearchResearch compoundLimited evidence

Thozalinone

Obsolete oxazolinone dopaminergic stimulant, once studied as the antidepressant Stimsen.

NootropicStimulantStimulantMoodDopamineNorepinephrine

Pharmacology

ClassStimulant · Mood
Primary targetDopaminergic stimulation (elevated dopamine synthesis and catecholamine tone)
Targets2 receptor targets
Half-lifeNo well-characterized human pharmacokinetic data
OnsetTypically earlier in the day given its stimulant nature
EvidenceLimited evidence
Affected systemsDopamineNorepinephrine

Contents

WHAT IS THOZALINONE?

Detailed overview

Thozalinone (CL 39,808, brand name Stimsen) is an oxazolinone-class central nervous system stimulant from the same chemical family as pemoline and fenozolone. It acts as a dopaminergic agent: in rodents it reliably elicits gnawing and stereotyped biting behavior that is blocked by dopamine-blocking drugs, confirming dopaminergic mediation. In the 1960s and 1970s it was investigated as an antidepressant and as an appetite-suppressing weight-loss agent in a handful of small clinical trials. Today it is an obsolete compound that has been essentially withdrawn from practice, with very limited modern safety and pharmacokinetic data.

Mechanism

Dopaminergic stimulant (oxazolinone)

Evidence

Limited, dated clinical data

Legal status

Obsolete, withdrawn drug

Receptor profile

  • Dopamine synthesis / dopaminergic signalingModerate
  • Catecholamine tone (dopamine, noradrenaline)Moderate

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Overstimulation, restlessness and tremor from the dopaminergic stimulant effect
  • Insomnia or disrupted sleep if taken too late in the day
  • Appetite suppression (the compound was also studied as a weight-loss agent)
  • Increased heart rate and blood pressure, as with other central stimulants
  • Theoretical risk of dependence and tolerance from the dopaminergic mode of action
  • An obsolete drug with very limited modern safety data

Contraindications · 5

  • Pregnancy and breastfeeding: safety not established, avoid
  • Cardiovascular disease, arrhythmia, uncontrolled hypertension
  • Anxiety disorders, panic disorder: the stimulant effect may worsen them
  • Avoid combining with MAO inhibitors or other dopaminergic/stimulant agents
  • A withdrawn, obsolete drug; not recommended without clinical supervision

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Obsolete oxazolinone dopaminergic stimulant, once studied as the antidepressant Stimsen.

Telegram

Have a question about Thozalinone?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC11H12N2O2
UpdatedJuly 10, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: July 10, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.